ライフサイエンスコーパス: EBOV

1 EBOV GP and RABV GP-specific antibody titers increased e

2 EBOV RNA and infectious EBOV was detected by real-time R

3 EBOV RNA was not detected in general ward spaces.

4 We present sequence data and analysis of 142 EBOV samples collected during the period March to Octobe

5 ted to the severity and scope of the 2013-16 EBOV epidemic.

6 f a convalescent donor who survived the 2014 EBOV Zaire outbreak.

7 -C05 or EBOV-C07 died of EVD, whereas 2 of 3 EBOV-K-infected animals died.

8 severe lung pathology was observed in 2 of 6 EBOV-C05/C07-infected macaques.

9 sequelae and to develop therapies to abolish EBOV persistence.

10 that inhibition of TLR4 signaling abolishes EBOV GP-mediated NF-kappaB activation.

11 s or therapeutics for the treatment of acute EBOV disease (EVD).

12 in a single injection at 1 or 24 hours after EBOV exposure or with 2 injections, half the dose at eac

13 animals may boost protective responses after EBOV challenge by maintaining transcriptional changes.

14 ne analogue, with antiviral activity against EBOV.

15 a small-molecule antiviral compound against EBOV in nonhuman primates.

16 antibody therapy has been developed against EBOV, named EBOTAb.

17 n the development of antiviral drugs against EBOV.

18 argeted for therapeutic intervention against EBOV infection.IMPORTANCE EBOV belongs to a family of hi

19 ate that EBOTAb conferred protection against EBOV when given post-exposure and should be explored and

20 al for rVSV-EBOV mediated protection against EBOV; however, the mechanisms by which this vaccine indu

21 hat EBOTAb is an effective treatment against EBOV disease, even when delivered late after infection.

22 ncreased efforts to develop vaccines against EBOV disease.

23 he most efficient molecules in vitro against EBOV infection.

24 Results of minigenome assays and an EBOV reverse genetic system rescue support a role for bo

25 tein family A (HSC70) member 8 (HSPA8) as an EBOV trailer-interacting host protein.

26 able, we assessed protection conferred by an EBOV vaccine composed of vesicular stomatitis virus pseu

27 ed by post, and samples were tested using an EBOV IgG capture assay that detects IgG to Ebola glycopr

28 his small animal model for studying BDBV and EBOV using wild-type isolates and will accelerate effort

29 U/test within 40 minutes for EBOV-Kikwit and EBOV-Makona, respectively.

30 tions from Lassa and Ebola viruses (LASV and EBOV, respectively).

31 5 times more sensitive in detecting LASV and EBOV, respectively, compared to that with ELISA.

32 sitive in detecting lower levels of LASV and EBOV, respectively.

33 ion and immune evasion observed for MARV and EBOV.

34 ted macaques after rVSV-EBOV vaccination and EBOV challenge.

35 ed nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases.

36 guide the development of more powerful anti-EBOV drugs.

37 ion effort identified 4b (GS-5734) with anti-EBOV EC50 = 86 nM in macrophages as the clinical candida

38 to diagnose presymptomatic and asymptomatic EBOV infections.

39 nt, bivalent, inactivated rabies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys.

40 ed sex unless their semen is confirmed to be EBOV free.

41 k native G glycoprotein (VSVDeltaG) and bear EBOV glycoprotein (GP).

42 cular stomatitis virus pseudovirions bearing EBOV glycoprotein (EBOV GP/VSVDeltaG), we evaluated viru

43 BD, we also tested whether VSVDeltaG bearing EBOV GPs that lack GP1 N-linked glycans provided effecti

44 physical and functional interaction between EBOV VP40 (eVP40) and WWP1, a host E3 ubiquitin ligase t

45 Both EBOV VP35 and VP24 IID were found to suppress the innate

46 counteract the threat of outbreaks caused by EBOV and related filoviruses.

47 Inhibition of IFN signaling by EBOV VP24 (eVP24) involves its interaction with the NPI-

48 capable of partially neutralizing a chimeric EBOV carrying BDBV GP in which expression of sGP was dis

49 cal countermeasures may not completely clear EBOV infection.

50 In contrast, EBOV VP35 is likely a tetramer in solution.

51 cells (macrophages/monocytes) as the cryptic EBOV reservoir cells in the vitreous humour and its imme

52 Consistent with previous data, EBOV infection is associated with a proinflammatory sign

53 Due to the migratory properties of DCs, EBOV infection of these cells has been proposed as a nec

54 ation well beyond viral clearance and detect EBOV-specific T cells.

55 e Ebola virus test can simultaneously detect EBOV and SUDV in 200 microL of whole blood.

56 The Filovirus Screen kit detected EBOV, Sudan virus, Tai Forest virus, Bundibugyo virus, R

57 assay is accurate and precise for detecting EBOV in whole semen.

58 Infection with high-dose EBOV resulted in rapid, lethal EVD with high viral loads

59 lls, which are early cellular targets during EBOV infection.

60 Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe h

61 een shown to be the primary source of Ebola (EBOV) transmission.

62 Ebolavirus (EBOV), an enveloped filamentous RNA virus causing severe

63 est for rapid detection of Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV).

64 Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebolavir

65 ultiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine

66 e that adopting miniaturized electrochemical EBOV immunosensing can detect virus level at pM concentr

67 s that regulate replication of eGFP-encoding EBOV minigenomic RNA and identified heat shock cognate p

68 riguingly, we also found that TRIM6 enhances EBOV polymerase activity in a minigenome assay and TRIM6

69 As expected, EBOV infection led to a profound proinflammatory respons

70 atients, and were heat treated to facilitate EBOV inactivation prior to PCR.

71 wever, there is no fully validated assay for EBOV detection in fluids other than blood.

72 A validated assay for EBOV RNA detection in semen informs the care of male sur

73 The Cepheid Xpert Ebola assay for EBOV RNA detection was validated for whole semen and blo

74 The 95% limits of detection for EBOV and SUDV were 465 plaque-forming units (PFU)/mL (10

75 and 1 x 10(3) PFU/test within 40 minutes for EBOV-Kikwit and EBOV-Makona, respectively.

76 a potential supportive treatment option for EBOV disease.IMPORTANCE Emerging infectious diseases are

77 V) to severe disease with fatal outcomes for EBOV.

78 ll lines, indicating that permissiveness for EBOV at cell and organism levels do not necessarily corr

79 ses demonstrated 100% correct reactivity for EBOV and SUDV and no cross-reactivity with relevant path

80 loop of NPC1, the endolysosomal receptor for EBOV.

81 experienced symptoms did not get tested for EBOV at the time, suggests a need to review and standard

82 hom 40 (70%) were not tested at the time for EBOV infection.

83 ently no approved vaccines or treatments for EBOV, a better understanding of the biology and function

84 d in SDS-treated plasma and whole blood from EBOV-infected nonhuman primates (NHPs).

85 at 1 or 2 dpi were also fully protected from EBOV infection.

86 pared the interactions of VP24 proteins from EBOV and two members of the Ebolavirus genus, Bundibugyo

87 ons (iSNVs) from deep-sequenced samples from EBOV-infected patients, through a well-tailored bioinfor

88 We have identified a novel and functional EBOV VP40 interactor, ITCH, that regulates VP40-mediated

89 rus pseudovirions bearing EBOV glycoprotein (EBOV GP/VSVDeltaG), we evaluated virus binding and entry

90 geting the Ebola virus surface glycoprotein (EBOV GP) are implicated in protection against lethal dis

91 e of patients suspected or confirmed to have EBOV disease.

92 es were associated with significantly higher EBOV replication in the liver but not in the spleen, sug

93 Until now, studying how EBOV disseminates into and persists in immune-privileged

94 or Makona (2014) isolates derived from human EBOV cases.

95 these autoantibodies was confirmed in human EBOV survivors.

96 In SGM3 HuMice, EBOV replicated to high levels, and disease was observed

97 -specific residues were also found to impact EBOV entry, with a total of 8 mTIM-4 and 14 hTIM-4 IgV d

98 available for clinical evaluation.IMPORTANCE EBOV hemorrhagic fever is one of the most lethal viral i

99 tervention against EBOV infection.IMPORTANCE EBOV belongs to a family of highly pathogenic viruses th

100 t ER-phagy is an important limiting event in EBOV replication in mouse cells and may have implication

101 age and disease were observed exclusively in EBOV-infected mice.

102 The viremia level was elevated 10-fold in EBOV-C05-infected animals, compared with EBOV-C07- or EB

103 importance of the MPER/TM-FL interaction in EBOV entry and fusion.

104 (EBOV), the cellular mechanisms involved in EBOV infection are still largely unknown.

105 by preventing the cytokine storm observed in EBOV infection.

106 ributes to the various illnesses observed in EBOV survivors.

107 of human filoviral disease were observed in EBOV-infected ferrets.

108 actor 3 (IRF3) and NF-kappaB was observed in EBOV-infected, but not in RESTV-infected, MDMs.

109 ve TLR4-mediated proinflammatory response in EBOV infection should be considered as a potential suppo

110 protein 30 (eVP30) plays a critical role in EBOV transcription initiation at the nucleoprotein (eNP)

111 4b on viral shedding from sanctuary sites in EBOV survivors.

112 0.1% detergent treatment did not inactivate EBOV in blood samples from infected NHPs.

113 0.1% SDS or Triton X-100 does not inactivate EBOV.

114 vious results, MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-ka

115 ninfected donors and spiked with inactivated EBOV.

116 e entry of many enveloped viruses, including EBOV.

117 not on a competitive assay or on an indirect EBOV IgG ELISA.

118 Infectious EBOV titers were determined in SDS-treated plasma and wh

119 EBOV RNA and infectious EBOV was detected by real-time RT-PCR and virus culture

120 cess and morphology of authentic, infectious EBOV.

121 cells have reduced replication of infectious EBOV, suggesting that VP35 hijacks TRIM6 to promote EBOV

122 w potent therapeutic efficacy against lethal EBOV challenge in mice.

123 f FILORAB1 to 100% protection against lethal EBOV challenge, with no to mild clinical signs of diseas

124 us macaque non-human primate model of lethal EBOV infection.

125 Remarkably, 77% of the mAbs neutralize live EBOV, and several mAbs exhibit unprecedented potency.

126 has an improved signal-to-noise ratio at low EBOV RNA concentrations and is somewhat more sensitive t

127 ked glycans on GP1 protected mice against ma-EBOV challenge, but these mutants were no more effective

128 challenge with mouse-adapted Ebola virus (ma-EBOV) in a dose-dependent manner.

129 effective immunity against challenge with ma-EBOV or a more distantly related virus, Sudan virus.

130 Ebola virus Makona (EBOV-Makona; from the 2013-2016 West Africa outbreak) sh

131 porary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture.

132 We observed no major or minor EBOV mutations within regions targeted by therapeutics.

133 BOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

134 d Scientific Research established a national EBOV diagnostic site at the University of Sciences, Tech

135 e mined the human immune response to natural EBOV infection and identified mAbs with exceptionally po

136 on of EBOV replication and protected 100% of EBOV-infected animals against lethal disease, ameliorati

137 infectivity may have enhanced the ability of EBOV to transmit among humans and contributed to the wid

138 BOTAb resulted in a decreased circulation of EBOV in the bloodstream.

139 id, selective and sensitive POC detection of EBOV for global health care.

140 rapid, user-friendly assay for detection of EBOV RNA in semen that is deployable to multiple sites a

141 3 days post-challenge with a lethal dose of EBOV.

142 more natural routes require higher doses of EBOV to produce disease or that there may be differences

143 V1) expressing the membrane-anchored form of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vacci

144 nderstanding of the biology and functions of EBOV-host interactions that promote or inhibit viral bud

145 plex with the cleaved glycoprotein (GPcl) of EBOV, both determined by single-particle electron cryomi

146 l new target for host-oriented inhibitors of EBOV egress.

147 Two separate introductions of EBOV occurred in Mali from neighboring Guinea, but both

148 t was initiated correspond to when levels of EBOV are detectable in the circulation and thus mimic wh

149 tested in the stringent guinea pig model of EBOV disease, EBOTAb has been shown to confer protection

150 promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus maca

151 say is optimal for large-scale monitoring of EBOV RNA persistence in male survivors.

152 tudy, to our knowledge, of the prevalence of EBOV infection in international responders.

153 this platform, provides robust protection of EBOV-challenged mice.

154 on conferred correlated with the quantity of EBOV GP-specific Ig produced but not with the production

155 3 ligases, ubiquitination, and regulation of EBOV VP40-mediated egress.IMPORTANCE Ebola virus (EBOV)

156 th mucosal surfaces is an important route of EBOV spread during a natural outbreak, and aerosols also

157 An important mechanism for the severity of EBOV infection is its suppression of innate immune respo

158 t, to our knowledge, unliganded structure of EBOV GP, and high-resolution complexes of GP with the an

159 In this comparative study of EBOV- and RESTV-infected human macrophages, we identifie

160 12 days resulted in profound suppression of EBOV replication and protected 100% of EBOV-infected ani

161 ousette bat (Rousettus aegyptiacus); that of EBOV is unknown but believed to be another bat species.

162 Infectious titers of EBOV or herpes simplex virus type 1 (HSV-1) in detergent

163 following the cross-species transmission of EBOV from an animal reservoir, most likely bats, into hu

164 alysis, the epidemiology and transmission of EBOV have been well elucidated.

165 iviral activity against multiple variants of EBOV and other filoviruses in cell-based assays.

166 cause disease in nonhuman primates, yet only EBOV causes disease in humans.

167 All animals infected with EBOV-C05 or EBOV-C07 died of EVD, whereas 2 of 3 EBOV-K-infected ani

168 infected animals, compared with EBOV-C07- or EBOV-K-infected animals.

169 ost innate immune response to either MARV or EBOV infection in bat and human cells and the role of vi

170 As reported for other EBOV vaccine platforms, the protection conferred correla

171 Here, we detect persistent EBOV replication coinciding with systematic inflammatory

172 onkeys could serve as a model for persistent EBOV infection in humans, and we demonstrate that promis

173 conclusion, our data suggest that persistent EBOV infection in rhesus monkeys could serve as a model

174 aboratory investigations revealed persisting EBOV RNA in the mother's breast milk and the father's se

175 17.5%) reported that they had had a possible EBOV exposure.

176 FILORAB1/GLA-SE as an effective preexposure EBOV vaccine.

177 phages and dendritic cells (DCs) are primary EBOV targets.

178 preclinical efficacy in a non-human-primate EBOV challenge model.

179 nonengrafted mice did not support productive EBOV replication or develop lethal disease.

180 We document progressive EBOV dissemination into the eyes, brain and testes throu

181 uggesting that VP35 hijacks TRIM6 to promote EBOV replication through ubiquitination.

182 important host cellular factor that promotes EBOV replication, and future studies will focus on wheth

183 However, a recombinant EBOV expressing a fluorescent protein tolerated swapping

184 ptional response seen in previously reported EBOV-exposed NHP studies.

185 rols and T-cell-depleted macaques after rVSV-EBOV vaccination and EBOV challenge.

186 ished that antibodies are essential for rVSV-EBOV mediated protection against EBOV; however, the mech

187 ere G protein is replaced with EBOV GP (rVSV-EBOV) is safe and highly efficacious.

188 ral response and the role of T-cells in rVSV-EBOV mediated protection remain poorly understood.

189 ed role for CD8(+) T-cells in mediating rVSV-EBOV protection.

190 We show that rVSV-EBOV vaccination induces gene expression changes consist

191 Histologic lesions with strong EBOV antigen staining were noted in the left eye (scleri

192 Genomic analysis strongly suggests EBOV transmission to the child through breastfeeding.

193 mouse and non-human primates which survived EBOV challenge, ELISA, western blot, mass spectrometry a

194 Many therapies under investigation target EBOV cell entry.

195 es, more in keeping with SUDV survivors than EBOV survivors.

196 The study demonstrated that EBOV and MARV replicate to similar levels in all tested

197 We show that EBOV does not induce formation of stress granules (SGs)

198 Our results show that EBOV GP/VSVDeltaG pseudovirions serve as a successful va

199 We further show that EBOV is unable to block SG formation triggered by exogen

200 hematopoietic-driven immunity, to show that EBOV primarily infects CD11b(+) DCs in non-lymphoid and

201 The EBOV genome encodes VP35, an important viral protein inv

202 The EBOV VP24 (eVP24) and MARV VP40 (mVP40) proteins each in

203 The EBOV VP35 protein contributes to pathogenesis, because i

204 The EBOV VP40 (eVP40) matrix protein is the main driving for

205 of iSNVs during this outbreak and along the EBOV genome.

206 Fusion is mediated by the EBOV envelope glycoprotein GP, which consists of subunit

207 These viral inclusions contain the EBOV nucleocapsids and are sites of viral replication an

208 an intranasal vaccine vector to express the EBOV glycoprotein GP.

209 However, the EBOV and SUDV glycoprotein (GP) sequences are 45% diverg

210 in amino acid sequence, such as A82V in the EBOV glycoprotein (GP) that occurred early in the 2013-1

211 hat specific amino acid substitutions in the EBOV GP have increased tropism for human cells, while re

212 h the previously determined structure of the EBOV FL through several critical aromatic residues.

213 e thought to shield conserved regions of the EBOV GP receptor-binding domain (RBD), thereby blocking

214 he TM domain: i.e., the missing parts of the EBOV GP2 structure.

215 n analysis of the secondary structure of the EBOV minigenomic RNA indicates formation of a small stem

216 n return, had OFSs that were reactive on the EBOV IgG capture assay, with similar results on plasma.

217 th HRSV, there was unique commonality to the EBOV variants.

218 Here, we present for the first time EBOV-induced changes in circulating miRNA populations of

219 questionnaire to determine their exposure to EBOV and their experience of illness.

220 s for the management of possible exposure to EBOV, and for the management of illness, across organisa

221 ive infection with MARV but is refractory to EBOV.

222 his study, we dissected the host response to EBOV and RESTV infection in primary human monocyte-deriv

223 cteristics of the human antibody response to EBOV GP remain poorly understood.

224 ome organisation and replication strategy to EBOV.

225 ndividuals who are especially susceptible to EBOV replication is possibly one of the many challenges

226 Herein we describe wild-type EBOV (Makona variant) infection of mice engrafted with h

227 izing activity against RABV and pseudo-typed EBOV.

228 Unmodified EBOV GP was packaged into the HPIV1 particle, and the TM

229 nd lack of licensed antivirals and vaccines, EBOV is listed as a tier 1 select-agent risk group 4 pat

230 n a genus distinct from that of Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus, respectively)

231 have shown that the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) suppress DC maturation in

232 Ebola virus (EBOV) and Reston virus (RESTV) are members of the Ebolav

233 Both Ebola virus (EBOV) and Reston virus (RESTV) cause disease in nonhuman

234 mmune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided th

235 Ebola virus (EBOV) causes severe systemic disease in humans and non-h

236 Rapid Ebola virus (EBOV) detection is crucial for appropriate patient manag

237 Diagnosis of Ebola virus (EBOV) disease (EVD) requires laboratory testing.

238 nment limited the 2014 Nigerian Ebola virus (EBOV) disease outbreak to 20 reported cases and 8 fatali

239 The 2013-2016 West African Ebola virus (EBOV) disease outbreak was the largest filovirus outbrea

240 A 9-month-old infant died from Ebola virus (EBOV) disease with unknown epidemiological link.

241 Aware of the rapid spread of Ebola virus (EBOV) during the current West African epidemic, Mali too

242 The recent Ebola virus (EBOV) epidemic in West Africa demonstrates the potential

243 The Ebola virus (EBOV) epidemic in West Africa increased the focus on vac

244 The Ebola virus (EBOV) genome encodes a partly conserved 40-residue nonst

245 ted one nonsynonymous mutation, Ebola virus (EBOV) glycoprotein (GP) mutant A82V, for its effect on v

246 The Ebola virus (EBOV) GP gene encodes two glycoproteins.

247 and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but various inventive s

248 Ebola virus (EBOV) infection is characterized by sporadic outbreaks c

249 A hallmark of Ebola virus (EBOV) infection is the formation of viral inclusions in

250 onhuman primate (NHP) models of Ebola virus (EBOV) infection primarily use parenteral or aerosol rout

251 al in which the patient cleared Ebola virus (EBOV) infection without experimental drugs allowed for t

252 disappointing in tests against Ebola virus (EBOV) infection, more recently, specific molecules have

253 ils ZMapp(TM) and MIL77 against Ebola virus (EBOV) infections have reignited interest in antibody-bas

254 promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition

255 VP40-mediated egress.IMPORTANCE Ebola virus (EBOV) is a high-priority, emerging human pathogen that c

256 Ebola virus (EBOV) is a member of the Filoviridae family and the caus

257 Ebola virus (EBOV) is a single-stranded negative-sense RNA virus belo

258 Ebola virus (EBOV) is an enveloped negative-sense RNA virus that caus

259 Ebola virus (EBOV) isolates derived directly from human specimens do

260 vaccine consisting of the 2014 Ebola virus (EBOV) Makona isolate.

261 whether treatment selected for Ebola virus (EBOV) mutations conferring resistance, viral sequencing

262 The recent Ebola virus (EBOV) outbreak in West Africa was the largest recorded i

263 The recent 2014-2016 Ebola virus (EBOV) outbreak prompted increased efforts to develop vac

264 ified by the recent devastating Ebola virus (EBOV) outbreak.

265 Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public heal

266 Ebola virus (EBOV) persistence in asymptomatic humans and Ebola virus

267 Ebola virus (EBOV) poses a significant threat to human health as high

268 ent studies have suggested that Ebola virus (EBOV) ribonucleic acid (RNA) potentially present in the

269 Ebola virus (EBOV) RNA persistence in semen, reported sexual transmis

270 Ebola virus (EBOV) survivors are affected by a variety of serious ill

271 tic test results and infectious Ebola virus (EBOV) titers.

272 Ferrets were also infected with Ebola virus (EBOV) to confirm their susceptibility to another filovir

273 The Ebola virus (EBOV) variant Makona (which emerged in 2013) was the cau

274 or transmission of West African Ebola virus (EBOV) variants, which are divergent from their Central A

275 The interaction of Ebola virus (EBOV) VP24 protein with host karyopherin alpha (KPNA) pr

276 (RABV) vectored vaccine against Ebola virus (EBOV), a major threat to wild chimpanzees and gorillas.

277 Ebola virus (EBOV), a member of the Filoviridae family, is a highly p

278 ridae family that also includes Ebola virus (EBOV), causes lethal hemorrhagic fever with case fatalit

279 fection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV

280 s against the highly pathogenic Ebola virus (EBOV), the cellular mechanisms involved in EBOV infectio

281 rticular risk of infection with Ebola virus (EBOV).

282 severe viral illness caused by Ebola virus (EBOV).

283 cosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host re

284 treated groups of animals with 1 dose of VSV-EBOV either in a single injection at 1 or 24 hours after

285 high-volume air sampler to determine whether EBOV could be detected during 3 independent studies with

286 ear understanding of the mechanisms by which EBOV causes such severe disease.

287 While EBOV causes a severe disease in humans characterized by

288 derstanding of the interaction of TIM-4 with EBOV virions.

289 in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differen

290 in EBOV-C05-infected animals, compared with EBOV-C07- or EBOV-K-infected animals.

291 fectiveness of the ReEBOV RDT, compared with EBOV-specific qRT-PCR.

292 All animals infected with EBOV-C05 or EBOV-C07 died of EVD, whereas 2 of 3 EBOV-K-

293 ized mice (hu-NSG-SGM3) were inoculated with EBOV or RESTV.

294 mbinant VSV where G protein is replaced with EBOV GP (rVSV-EBOV) is safe and highly efficacious.

295 e detected during 3 independent studies with EBOV-challenged NHPs.

296 selected SG proteins are sequestered within EBOV inclusions, where they form distinct granules that

297 iginal Xpert EBOV assay), the modified Xpert EBOV assay demonstrated greater sensitivity than the com

298 Thus, the modified Xpert EBOV assay is optimal for large-scale monitoring of EBOV

299 se chain reaction assays, and original Xpert EBOV assay), the modified Xpert EBOV assay demonstrated

300 In this study, we optimized the Xpert EBOV assay for semen samples by adding dithiothreitol.